nature research

Corresponding author(s):	Zhifa Shen, Zaisheng Wu
Last undated by author(s):	Eah 8, 2021

Reporting Summary

Nature Research wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Research policies, see our <u>Editorial Policies</u> and the <u>Editorial Policy Checklist</u>.

CS

For a	all statistical ar	halyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.				
n/a	Confirmed					
	The exact	ct sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement				
	🗶 A stateme	ent on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly				
		tical test(s) used AND whether they are one- or two-sided non tests should be described solely by name; describe more complex techniques in the Methods section.				
x	A descript	description of all covariates tested				
×	A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons					
	A full desc AND varia	all description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) O variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)				
x		full hypothesis testing, the test statistic (e.g. F , t , r) with confidence intervals, effect sizes, degrees of freedom and P value noted P values as exact values whenever suitable.				
x	For Bayes	Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings				
x	For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes					
Estimates of effect sizes (e.g. Cohen's d, Pearson's r), indicating how they were calculated						
Our web collection on <u>statistics for biologists</u> contains articles on many of the points above.						
Sof	ftware an	d code				
Polic	cy information	about <u>availability of computer code</u>				
Da	ta collection	no software was used				
Data analysis		Statistical significance was assessed using either Excel or GraphPad Prism8. Grey values for Western Blotting and immunofluorescence quantification were analyzed using Image J.				
		g custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and				

Data

Policy information about availability of data

All manuscripts must include a <u>data availability statement</u>. This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A list of figures that have associated raw data
- A description of any restrictions on data availability

We declare that the data supporting the findings of this study are available within the paper and its supplementary information files.

Life sciences study design

	.000 000	<i>x</i> 4 4 4 5 6 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7	
All studies must dis	sclose on these	points even when the disclosure is negative.	
Sample size	No sample size was predetermined. Three or more independent samples were used to obtain results which were then used to perform statistical analysis. All sample sizes and the number of independent replicates are stated in figure legends.		
Data exclusions	none.		
Replication	The number of	independent biological replicates are described in figure legends	
Randomization	The samples we	ere randomly allocated into experimental group.	
Blinding	The investigato	rs were blinded to group allocation during data collection and analysis.	
We require informatis system or method liss Materials & ex n/a Involved in th	ion from authors a ted is relevant to perimental so ne study so cell lines logy and archaeol nd other organism search participant	n/a Involved in the study ChIP-seq Flow cytometry MRI-based neuroimaging State	
<u>Antibodies</u>			
Antibodies used	STAT3, Cell Signaling Technology, 8768S, D1A5; p-STAT3, Cell Signaling Technology, 9131S, D3A7; FMRP, abcam, ab17722, GR3266123-1; LaminB1, proteintech, 12987-1-AP; β-actin, proteintech, 20536-1-AP.		
Validation	All antibodies that are commercially available have been tested for species reactivity and application by the manufacturers.		
Eukaryotic c	ell lines		
Policy information	about <u>cell lines</u>		
Cell line source(s)		The cell lines were obtained from the Chinese Academy of Sciences. The Chinese Academy of Sciences purchased the cell lines from ATCC.	
Authentication		The authentication of all cell lines used was performed by short tandem repeat (STR)-profiling.	
Mycoplasma contamination All cell lines tes		All cell lines tested negative for mycoplasma contamination.	
Commonly misidentified lines (See ICLAC register)		No misidentified cell lines were used in this study.	
Animals and	l other org	ganisms	
Policy information	about <u>studies ir</u>	nvolving animals; ARRIVE guidelines recommended for reporting animal research	
Laboratory animals	aboratory animals BALB/C-nu nude mice, male, 6 week		
Wild animals	N/A		
Field-collected sam	amples The study did not involve samples collected from the field.		
Ethics oversight All animal experiments were approved by the Zhejiang Management Committee for Medical Laboratory Animal Science		mal experiments were approved by the Zhejiang Management Committee for Medical Laboratory Animal Sciences.	

Note that full information on the approval of the study protocol must also be provided in the manuscript.